Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model
Abstract Quantitative in vivo monitoring of cell biodistribution offers assessment of treatment efficacy in real-time and can provide guidance for further optimization of chimeric antigen receptor (CAR) modified cell therapy. We evaluated the utility of a non-invasive, serial 89Zr-oxine PET imaging...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1a42eddcd18d4b17b25c6a34627d8118 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1a42eddcd18d4b17b25c6a34627d8118 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1a42eddcd18d4b17b25c6a34627d81182021-12-02T17:55:09ZSpatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model10.1038/s41598-021-94490-02045-2322https://doaj.org/article/1a42eddcd18d4b17b25c6a34627d81182021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94490-0https://doaj.org/toc/2045-2322Abstract Quantitative in vivo monitoring of cell biodistribution offers assessment of treatment efficacy in real-time and can provide guidance for further optimization of chimeric antigen receptor (CAR) modified cell therapy. We evaluated the utility of a non-invasive, serial 89Zr-oxine PET imaging to assess optimal dosing for huLym-1-A-BB3z-CAR T-cell directed to Lym-1-positive Raji lymphoma xenograft in NOD Scid-IL2Rgammanull (NSG) mice. In vitro experiments showed no detrimental effects in cell health and function following 89Zr-oxine labeling. In vivo experiments employed simultaneous PET/MRI of Raji-bearing NSG mice on day 0 (3 h), 1, 2, and 5 after intravenous administration of low (1.87 ± 0.04 × 106 cells), middle (7.14 ± 0.45 × 106 cells), or high (16.83 ± 0.41 × 106 cells) cell dose. Biodistribution (%ID/g) in regions of interests defined over T1-weighted MRI, such as blood, bone, brain, liver, lungs, spleen, and tumor, were analyzed from PET images. Escalating doses of CAR T-cells resulted in dose-dependent %ID/g biodistributions in all regions. Middle and High dose groups showed significantly higher tumor %ID/g compared to Low dose group on day 2. Tumor-to-blood ratios showed the enhanced extravascular tumor uptake by day 2 in the Low dose group, while the Middle dose showed significant tumor accumulation starting on day 1 up to day 5. From these data obtained over time, it is apparent that intravenously administered CAR T-cells become trapped in the lung for 3–5 h and then migrate to the liver and spleen for up to 2–3 days. This surprising biodistribution data may be responsible for the inactivation of these cells before targeting solid tumors. Ex vivo biodistributions confirmed in vivo PET-derived biodistributions. According to these studies, we conclude that in vivo serial PET imaging with 89Zr-oxine labeled CAR T-cells provides real-time monitoring of biodistributions crucial for interpreting efficacy and guiding treatment in patient care.Naomi S. Sta MariaLeslie A. KhawliVyshnavi PachipulusuSharon W. LinLong ZhengDaniel CohrsXiaodan LiuPeisheng HuAlan L. EpsteinRussell E. JacobsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Naomi S. Sta Maria Leslie A. Khawli Vyshnavi Pachipulusu Sharon W. Lin Long Zheng Daniel Cohrs Xiaodan Liu Peisheng Hu Alan L. Epstein Russell E. Jacobs Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| description |
Abstract Quantitative in vivo monitoring of cell biodistribution offers assessment of treatment efficacy in real-time and can provide guidance for further optimization of chimeric antigen receptor (CAR) modified cell therapy. We evaluated the utility of a non-invasive, serial 89Zr-oxine PET imaging to assess optimal dosing for huLym-1-A-BB3z-CAR T-cell directed to Lym-1-positive Raji lymphoma xenograft in NOD Scid-IL2Rgammanull (NSG) mice. In vitro experiments showed no detrimental effects in cell health and function following 89Zr-oxine labeling. In vivo experiments employed simultaneous PET/MRI of Raji-bearing NSG mice on day 0 (3 h), 1, 2, and 5 after intravenous administration of low (1.87 ± 0.04 × 106 cells), middle (7.14 ± 0.45 × 106 cells), or high (16.83 ± 0.41 × 106 cells) cell dose. Biodistribution (%ID/g) in regions of interests defined over T1-weighted MRI, such as blood, bone, brain, liver, lungs, spleen, and tumor, were analyzed from PET images. Escalating doses of CAR T-cells resulted in dose-dependent %ID/g biodistributions in all regions. Middle and High dose groups showed significantly higher tumor %ID/g compared to Low dose group on day 2. Tumor-to-blood ratios showed the enhanced extravascular tumor uptake by day 2 in the Low dose group, while the Middle dose showed significant tumor accumulation starting on day 1 up to day 5. From these data obtained over time, it is apparent that intravenously administered CAR T-cells become trapped in the lung for 3–5 h and then migrate to the liver and spleen for up to 2–3 days. This surprising biodistribution data may be responsible for the inactivation of these cells before targeting solid tumors. Ex vivo biodistributions confirmed in vivo PET-derived biodistributions. According to these studies, we conclude that in vivo serial PET imaging with 89Zr-oxine labeled CAR T-cells provides real-time monitoring of biodistributions crucial for interpreting efficacy and guiding treatment in patient care. |
| format |
article |
| author |
Naomi S. Sta Maria Leslie A. Khawli Vyshnavi Pachipulusu Sharon W. Lin Long Zheng Daniel Cohrs Xiaodan Liu Peisheng Hu Alan L. Epstein Russell E. Jacobs |
| author_facet |
Naomi S. Sta Maria Leslie A. Khawli Vyshnavi Pachipulusu Sharon W. Lin Long Zheng Daniel Cohrs Xiaodan Liu Peisheng Hu Alan L. Epstein Russell E. Jacobs |
| author_sort |
Naomi S. Sta Maria |
| title |
Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| title_short |
Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| title_full |
Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| title_fullStr |
Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| title_full_unstemmed |
Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model |
| title_sort |
spatio-temporal biodistribution of 89zr-oxine labeled hulym-1-a-bb3z-car t-cells by pet imaging in a preclinical tumor model |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/1a42eddcd18d4b17b25c6a34627d8118 |
| work_keys_str_mv |
AT naomisstamaria spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT leslieakhawli spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT vyshnavipachipulusu spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT sharonwlin spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT longzheng spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT danielcohrs spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT xiaodanliu spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT peishenghu spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT alanlepstein spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel AT russellejacobs spatiotemporalbiodistributionof89zroxinelabeledhulym1abb3zcartcellsbypetimaginginapreclinicaltumormodel |
| _version_ |
1718379092005355520 |